argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
argenex (NASDAQ:ARGX) had its price target raised by analysts at Wells Fargo & Company from $1,095.00 to $1,316.00. They now have an "overweight" rating on the stock.
argenex (NASDAQ:ARGX) had its price target raised by analysts at Stifel Nicolaus from $1,028.00 to $1,248.00. They now have a "buy" rating on the stock.
argenex (NASDAQ:ARGX) had its price target raised by analysts at JPMorgan Chase & Co. from $925.00 to $1,100.00. They now have an "overweight" rating on the stock.
argenex (NASDAQ:ARGX) had its price target raised by analysts at Morgan Stanley from $1,070.00 to $1,110.00. They now have an "overweight" rating on the stock.